analogues du glp 1 GLP-1 versus inhibiteurs du SGLT-2 pour les diabétiques de type 2 obèses GLP-1-based therapies for type 2

B., Shah N., Gomoll A

We are excited to see Boehringer Ingelheim continue advancing this promising program, which combines a differentiated triple agonist approach with the potential to address significant unmet needs in obesity and related metabolic diseases. BI 3034701 represents a novel mechanism of action and is a potential first-in-class GLP-1/GIP/NYP2 receptor agonist designed to address obesity through three complementary biological pathways, where neuropeptide Y2 (NPY2)-driven central control of hunger, appetite, and food intake is complemented by GLP-1/GIP-mediated satiety, weight reduction, and metabolic regulation

Adrenal Fatigue occurs when your adrenal glands become overwhelmed in the face of chronic stress

10.1186/s13020-024-01022-9 61 JomovaK.AlomarS

Total oxidant capacity and antioxidant capacity levels as well as glutamate and glutamine concentrations were analyzed in the hippocampi

Oncol Res 16: 507516